Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
Mariona Riudavets, Marie Naigeon, Matthieu Texier, Miriam Leandro Dorta, Fabrice Barlési, Julien Mazières, Andréa Varga, Lydie Cassard, Lisa Boselli, Jonathan Grivel, Maud Ngo‐Camus, Ludovic Lacroix, Laura Mezquita, Benjamin Besse, Nathalie Chaput, David Planchard
Topics & Concepts
MedicineTremelimumabTolerabilityInternal medicineGefitinibCohortLung cancerRefractory (planetary science)OncologyGastroenterologyCancerAdverse effectEpidermal growth factor receptorImmunotherapyAstrobiologyPhysicsIpilimumabLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research